Aalto Bio Reagents Announces Availability of Mouse Monoclonal Antibody
Product News Jan 17, 2018
Aalto Bio Reagents its pleased to announce availability of its new mouse monoclonal antibody to Helicobacter pylori flagellin for diagnostic test manufacturers, vaccine developers and researchers globally. H. pylori is a gram-negative bacterium living in the mucus of the human digestive tract. It is a ubiquitous organism which is present in 50% of the global population; however it can lead to a variety of serious upper gastrointestinal disorders such as chronic gastritis, peptic ulcer disease and gastric cancer. According to research by the CDC, more than 90% of duodenal ulcers and up to 80% of gastric ulcers are caused by H. pylori infection.
Diagnosis of infection is accomplished by non-invasive methods, such as detection of H. pylori antigens in stool sample or by determination of IgG, IgA or IgM antibodies to H. pylori in human serum samples. Aalto Bio Reagents is pleased to announce availability of our monoclonal antibody to H. pylori flagellin which is self-pairing and can be used as both capture and label elements in immunoassay development.
The global H. pylori market is expected to grow steadily from 2017 - 2027 with a compound annual growth rate of 8.23%. This is on account of an increasing ageing population combined with an increased prevalence of infectious diseases and gastritis. The rapid advances in the field of in-vitro diagnostics in addition to the increasing approval rate for immunodiagnostic tests, are expected to further propel the market growth of H. pylori.
Philip Noone, CEO of Aalto Bio Reagents, said “the welcome addition of our MAb to H. pylori strengthens our presence in this growing area with our already well-established, native H. pylori antigen. This hugely successful antigen is being used for production of a number of IgG, IgA and IgM ELISAs which are CE marked and currently on the market, as well as in the production of ChLIA and lateral flow assays. Our industry has an unrelenting requirement for access to the most scientifically proven raw materials, a broader range of flexible controls and faster diagnostics. With our H. pylori MAb and native antigen solution, we are truly building a comprehensive range of materials to meet our customer’s needs. We envisage that our H. pylori MAb and protein will provide the critical element to further diagnostic companies’ research and development of assays. We will continue to focus on the expansion of our IVD products with even more additions in 2018-19, to enable our customers to bring superior, best-in-class diagnostic products to market faster, and aid in the development of life-saving vaccines.”